Enclomiphene & Clomiphene: The Complete Guide

Overview

Clomiphene citrate is a racemic mixture of two geometric isomers: enclomiphene (trans-clomiphene) and zuclomiphene (cis-clomiphene). These two isomers have different pharmacological profiles. Enclomiphene is the more potent anti-estrogenic isomer and is primarily responsible for the hypothalamic estrogen receptor blockade that drives testosterone production. Zuclomiphene has weaker anti-estrogenic activity, a longer half-life, and accumulates in tissue over time — contributing to some of clomiphene's estrogenic side effects (Krzastek et al., 2019).

The commercial formulation of clomiphene citrate (Clomid, Serophene) contains approximately 62% enclomiphene and 38% zuclomiphene. The development of pure enclomiphene (marketed under the investigational name Androxal by Repros Therapeutics) was intended to deliver the testosterone-boosting benefits of clomiphene while reducing estrogenic side effects associated with zuclomiphene accumulation (Kaminetsky et al., 2013).

For men with secondary hypogonadism — low testosterone caused by insufficient signaling from the hypothalamus or pituitary rather than testicular failure — clomiphene and enclomiphene represent a fundamentally different approach from exogenous testosterone. Testosterone replacement therapy (TRT) suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing or eliminating sperm production and causing testicular atrophy. Clomiphene and enclomiphene stimulate the HPG axis, increasing both testosterone and sperm production simultaneously.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

The Hypothalamic-Pituitary-Gonadal (HPG) Axis

Testosterone production is regulated by a feedback loop involving three structures:

1. Hypothalamus — releases gonadotropin-releasing hormone (GnRH) in pulsatile fashion
2. Anterior pituitary — responds to GnRH by releasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
3. Testes — LH acts on Leydig cells to produce testosterone; FSH acts on Sertoli cells to support spermatogenesis

When circulating testosterone (and its aromatized product, estradiol) rises, it feeds back to the hypothalamus and pituitary to reduce GnRH, LH, and FSH secretion. This negative feedback loop maintains testosterone within a physiological range.

SERM Mechanism: Blocking Estrogen Feedback

Estradiol (E2) — produced by aromatization of testosterone — is the primary negative feedback signal at the hypothalamus. Clomiphene and enclomiphene act as competitive antagonists at hypothalamic estrogen receptors, blocking estradiol from exerting its suppressive effect. The hypothalamus "perceives" low estrogen and responds by increasing GnRH pulse frequency. This cascades through the axis:

• Increased GnRH → increased pituitary LH and FSH secretion
• Increased LH → Leydig cells produce more testosterone
• Increased FSH → Sertoli cells support more robust spermatogenesis

The critical distinction from exogenous testosterone: the body's own production machinery is stimulated, not bypassed. Intratesticular testosterone — essential for spermatogenesis — is maintained or increased, rather than suppressed (Krzastek et al., 2019).

Enclomiphene vs. Zuclomiphene

The two isomers in clomiphene have distinct properties:

Because zuclomiphene accumulates with chronic dosing due to its long half-life, men taking clomiphene long-term may experience increasing estrogenic side effects over time. Pure enclomiphene avoids this accumulation, which was the rationale for developing it as a separate pharmaceutical product (Wiehle et al., 2014).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Clomiphene for Male Hypogonadism

Clomiphene citrate has been used off-label for male hypogonadism for decades. Key evidence includes:

• Krzastek et al. (2019) — A comprehensive review of clomiphene use in male hypogonadism published in Current Urology Reports. The authors analyzed the available literature and concluded that clomiphene citrate represents an effective alternative to TRT in appropriately selected men with secondary hypogonadism, with the advantage of preserving spermatogenesis. Studies reviewed showed consistent testosterone increases from hypogonadal to eugonadal ranges, with improvements in symptoms of hypogonadism including energy, libido, and mood (PubMed).
• Testosterone normalization: Multiple retrospective studies have demonstrated that clomiphene 25–50 mg daily or every other day raises total testosterone from the hypogonadal range (typically <300 ng/dL) to the eugonadal range (450–800+ ng/dL) in the majority of men with secondary hypogonadism (Moskovic et al., 2012).
• Fertility preservation: Unlike exogenous testosterone, which suppresses spermatogenesis through HPG axis suppression, clomiphene maintains or improves sperm parameters. This is particularly relevant for hypogonadal men who wish to conceive. Studies have documented maintained or improved sperm concentration, motility, and morphology during clomiphene treatment (Krzastek et al., 2019).
• Long-term data: Retrospective cohorts with follow-up periods of 1–3 years have shown sustained testosterone elevation without tachyphylaxis (loss of response over time) in most patients. Some long-term users have been on clomiphene for 5+ years in clinical practice (Moskovic et al., 2012).

Enclomiphene (Androxal) Clinical Trials

Repros Therapeutics developed enclomiphene citrate (Androxal) specifically for male hypogonadism. Key trial data:

• Kaminetsky et al. (2013) — A randomized, double-blind Phase 2 trial comparing enclomiphene to topical testosterone gel (AndroGel) and placebo. Enclomiphene 12.5 mg and 25 mg daily normalized serum testosterone in hypogonadal men while maintaining or increasing LH and FSH levels. In contrast, testosterone gel suppressed LH and FSH to near-undetectable levels. Sperm concentrations were preserved in the enclomiphene group but significantly reduced in the testosterone gel group (PubMed).
• Wiehle et al. (2014) — Published results from enclomiphene studies demonstrating that enclomiphene citrate raised total testosterone levels into the normal range while maintaining sperm counts above the threshold for fertility (≥20 million/mL). The study confirmed the pharmacological rationale for isolating enclomiphene from the racemic mixture: more predictable pharmacokinetics, fewer estrogenic effects, and no zuclomiphene tissue accumulation (PubMed).
• Phase 3 trials: Repros Therapeutics completed two Phase 3 trials (ZA-301 and ZA-302). Both met primary endpoints for testosterone normalization. However, in 2015, the FDA issued a Complete Response Letter (CRL) for the Androxal NDA, citing concerns about trial design, the appropriateness of the endpoints, and the need for additional cardiovascular safety data. Repros did not resubmit, and the company was subsequently acquired. Androxal never reached the market as an FDA-approved product.

Comparative Studies: Clomiphene vs. TRT

• Hormonal outcomes: Both clomiphene and TRT normalize serum testosterone. However, clomiphene achieves this through endogenous production (LH/FSH rise), while TRT provides exogenous testosterone (LH/FSH suppressed). Intratesticular testosterone — critical for spermatogenesis — is maintained with clomiphene but suppressed with TRT (Krzastek et al., 2019).
• Symptom improvement: Studies have shown improvements in energy, libido, mood, and body composition with both clomiphene and TRT. Some clinicians report that a subset of patients experience less robust symptom improvement with clomiphene compared to TRT, though controlled comparative data is limited.
• Fertility: This is the critical differentiator. Clomiphene preserves or improves fertility; TRT suppresses it. For men of reproductive age or those who may want to conceive in the future, this distinction is clinically significant.

Limitations of the Evidence

• No FDA approval for men: Clomiphene is FDA-approved only for female ovulation induction. All male use is off-label.
• Limited RCT data for clomiphene in men: Most evidence for clomiphene in male hypogonadism comes from retrospective studies and case series rather than large randomized controlled trials.
• Enclomiphene never approved: Despite positive Phase 3 data, the FDA did not approve Androxal. The regulatory concerns were related to trial design and cardiovascular safety data requirements — not to demonstrated safety problems.
• Long-term safety data: While clomiphene has been used for decades, there are no large prospective studies specifically evaluating long-term safety in men taking it chronically for hypogonadism.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indication (Clomiphene Only)

Female ovulatory dysfunction: Clomiphene citrate (Clomid, Serophene) is FDA-approved for the treatment of ovulatory failure in women desiring pregnancy. It stimulates ovulation by blocking estrogen receptors at the hypothalamus, increasing FSH and LH release, promoting follicular development and ovulation. Typical female dosing is 50–100 mg daily for 5 days, starting on cycle day 3 or 5.

Off-Label Uses in Men

Ideal Candidates

Clomiphene and enclomiphene are most appropriate for men who:

• Have confirmed secondary hypogonadism (low testosterone with low or inappropriately normal LH/FSH)
• Want to preserve fertility or maintain the option for future conception
• Prefer oral medication over injectable testosterone
• Have contraindications to or prefer to avoid exogenous testosterone
• Are transitioning off TRT and need HPG axis recovery support

Who Should Not Use Clomiphene/Enclomiphene

• Primary hypogonadism: Men with testicular failure (elevated LH/FSH, damaged or absent testes) will not respond — the testes cannot produce more testosterone regardless of LH stimulation.
• Pituitary tumors or disorders: Conditions affecting pituitary function may alter the expected response to SERMs.
• Liver disease: Clomiphene is hepatically metabolized. Significant liver impairment may affect drug levels and increase side effect risk.
• History of thromboembolic events: SERMs carry a theoretical risk of thromboembolism, though the risk with clomiphene in men appears to be very low.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Commonly Reported Protocols

Dosing protocols derived from: Krzastek et al., 2019 · Kaminetsky et al., 2013 · Wiehle et al., 2014

Titration and Monitoring

Standard monitoring for clomiphene/enclomiphene therapy includes:

• Baseline labs: Total testosterone, free testosterone, LH, FSH, estradiol, CBC, comprehensive metabolic panel, lipid panel. Semen analysis if fertility is a primary concern.
• Follow-up labs (4–6 weeks): Repeat total testosterone, free testosterone, LH, FSH, estradiol. Adjust dose based on response.
• Target: Most providers aim for total testosterone in the mid-to-upper normal range (500–900 ng/dL) with LH and FSH in the normal to moderately elevated range, confirming HPG axis stimulation.
• Estradiol monitoring: Because clomiphene raises testosterone, aromatization to estradiol also increases. If estradiol rises excessively (typically >40–50 pg/mL), providers may reduce the dose or add a low-dose aromatase inhibitor.
• Ongoing monitoring: Labs every 3–6 months once a stable dose is established. Annual comprehensive metabolic panel, lipid panel, and PSA (in age-appropriate men).

Cycling Considerations

There is no established requirement for cycling clomiphene or enclomiphene. Many men use clomiphene continuously for years in clinical practice. Some providers recommend periodic reassessment with temporary discontinuation to assess whether the HPG axis has normalized. Others maintain continuous therapy if the underlying cause of hypogonadism (e.g., obesity, metabolic syndrome) has not been corrected.

Storage

• Clomiphene tablets: Store at room temperature (20–25°C / 68–77°F), protected from light and moisture.
• Compounded enclomiphene capsules: Store per compounding pharmacy instructions, typically at room temperature. Some compounding formulations may require refrigeration — follow the pharmacy's labeling.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Users Report

Reported Timeline

Laboratory Results

Published data on typical laboratory responses:

• Total testosterone: Average increase from ~250 ng/dL to ~550–700 ng/dL in responders. Individual variation is significant — some men exceed 900 ng/dL; some respond modestly (Moskovic et al., 2012).
• LH: Typically increases 1.5–3x from baseline, confirming pituitary stimulation.
• FSH: Increases in parallel with LH, supporting spermatogenesis.
• Estradiol: Increases proportionally with testosterone due to aromatization. Monitoring is important to avoid supraphysiological estradiol levels.
• Sperm parameters: Maintained or improved in most men. Contrast with TRT, where sperm concentration drops to <1 million/mL in ~65% of men within 6 months (Kaminetsky et al., 2013).

Non-Responders

Not all men respond to clomiphene or enclomiphene. Non-response or suboptimal response is more common in:

• Men with primary hypogonadism (testicular failure — elevated baseline LH/FSH)
• Men with severe obesity (BMI >40), where aromatase activity may convert additional testosterone to estradiol
• Older men (>65) with age-related decline in Leydig cell responsiveness
• Men with pituitary dysfunction or damage

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Reported Side Effects

Visual Disturbances: Important Safety Note

Visual side effects are the most clinically significant concern with clomiphene. They include blurred vision, scotomata (blind spots), visual trails (afterimages), and photopsia (flashing lights). These effects are attributed primarily to zuclomiphene accumulation in ocular tissues and are generally reversible upon discontinuation. In rare cases, prolonged use at high doses has been associated with more persistent visual changes.

If any visual disturbance occurs during clomiphene therapy, the medication should be discontinued immediately and an ophthalmologic evaluation should be performed. This is the most important safety monitoring point for clomiphene use.

Enclomiphene carries a lower risk of visual disturbances because it does not contain zuclomiphene, the isomer primarily implicated in ocular side effects.

Estradiol Management

Because clomiphene and enclomiphene raise testosterone, aromatization leads to proportional estradiol increases. Elevated estradiol can cause:

• Water retention
• Mood changes (emotional lability, anxiety)
• Gynecomastia (breast tissue development)
• Reduced efficacy of the SERM (high estradiol competing at receptors)

Providers monitor estradiol levels and may adjust the SERM dose or, in some cases, add a low-dose aromatase inhibitor to manage estradiol.

Drug Interactions

• Aromatase inhibitors: Sometimes combined intentionally to manage estradiol, but requires careful monitoring.
• Other SERMs (tamoxifen, raloxifene): Concurrent use is generally unnecessary and may produce unpredictable receptor interactions.
• Hepatically metabolized drugs: Clomiphene is metabolized by the liver via CYP enzymes. Significant CYP inhibitors or inducers may alter clomiphene levels, though clinically significant interactions are uncommonly reported.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

Clomiphene Citrate (Clomid)

• FDA approval: Approved for the treatment of ovulatory failure in women desiring pregnancy. Originally approved in 1967.
• Generic availability: Widely available as generic clomiphene citrate in 50 mg tablets. Multiple generic manufacturers.
• Off-label male use: Prescribing clomiphene to men for hypogonadism is legal and widely practiced in urology and endocrinology. Off-label prescribing is a standard and legal practice in medicine when supported by clinical evidence.
• Insurance coverage: Variable. Some insurance plans cover generic clomiphene when prescribed for a diagnosis of hypogonadism; others do not. The low cash price ($10–$30/month) makes this less of a barrier than for many medications.

Enclomiphene (Androxal)

• FDA status: Not approved. Repros Therapeutics submitted a New Drug Application (NDA) for Androxal (enclomiphene citrate) for secondary hypogonadism in men. The FDA issued a Complete Response Letter (CRL) in 2015, requesting additional cardiovascular safety data and raising concerns about trial design. Repros did not resubmit the NDA.
• Compounding availability: Enclomiphene is currently available through 503A and some 503B compounding pharmacies as a patient-specific preparation. Compounding pharmacies can prepare enclomiphene capsules (typically 12.5 mg or 25 mg) with a valid prescription from a licensed provider.
• Regulatory risk: The FDA's stance on compounding bulk substances that have been the subject of failed or withdrawn NDAs is complex. Enclomiphene's compounding availability could potentially be challenged, though no specific enforcement action has been taken to date.

DEA/Controlled Substance Status

Neither clomiphene nor enclomiphene is a controlled substance. They are not scheduled by the DEA. They are prescription medications but do not carry the regulatory restrictions associated with controlled substances (no special prescribing requirements, no prescription limits, no DEA registration needed).

WADA Status

Clomiphene is prohibited by WADA under Section S4 (Hormone and Metabolic Modulators) — specifically as an anti-estrogenic substance. Athletes subject to WADA testing cannot use clomiphene without a Therapeutic Use Exemption (TUE), which is rarely granted for this indication. Enclomiphene falls under the same prohibition.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

Insurance coverage for clomiphene in men varies by plan:

• With coverage: Copay is typically $0–$15 for generic clomiphene at most pharmacies.
• Without coverage: Cash price is $10–$30/month — low enough that lack of insurance coverage is rarely a significant barrier.
• Enclomiphene: Not covered by any insurance plan (compounded, non-FDA-approved). All costs are out-of-pocket.

Cost Comparison: Clomiphene/Enclomiphene vs. Other Hormone Optimization Approaches

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Question: Is clomiphene the same as testosterone replacement?

Answer: No. Clomiphene and TRT both raise serum testosterone, but through fundamentally different mechanisms. TRT provides exogenous testosterone, which suppresses the HPG axis — reducing LH, FSH, and sperm production. Clomiphene stimulates endogenous testosterone production by blocking estrogen feedback at the hypothalamus, which increases LH and FSH. The result is higher testosterone and preserved or improved spermatogenesis. This mechanistic difference makes clomiphene the preferred option for men who want to maintain fertility (Krzastek et al., 2019).

Question: Is enclomiphene better than clomiphene?

Answer: Enclomiphene has pharmacological advantages: a shorter half-life (~10 hours vs. zuclomiphene's ~30 days), purely anti-estrogenic activity (no zuclomiphene's estrogenic effects), and no tissue accumulation with chronic use. Clinical trial data showed effective testosterone normalization with a favorable side effect profile (Wiehle et al., 2014). However, "better" depends on context. Clomiphene is FDA-approved (for women), has decades of clinical experience in men, costs less, and is available at every pharmacy. Enclomiphene requires compounding, costs more, and has never been FDA-approved. Many men do well on clomiphene without significant side effects from the zuclomiphene component.

Question: Will clomiphene cause gynecomastia (breast tissue growth)?

Answer: Clomiphene is a SERM — it blocks estrogen receptors. In theory, this should protect against gynecomastia. However, because clomiphene raises testosterone, and testosterone is aromatized to estradiol, total estradiol levels increase. If estradiol rises disproportionately (particularly in men with higher body fat and greater aromatase activity), gynecomastia can occur despite the SERM's protective effect. This is uncommon and manageable with dose adjustment or estradiol monitoring (Krzastek et al., 2019).

Question: Can clomiphene be used permanently?

Answer: There is no established maximum duration for clomiphene use in men. Some men have used it continuously for years in clinical practice without apparent loss of efficacy or emerging safety signals (Moskovic et al., 2012). However, long-term prospective safety studies specifically evaluating chronic clomiphene use in men do not exist. Periodic reassessment of the need for continued therapy — and monitoring for side effects including visual changes — is standard practice.

Question: Does clomiphene work as well as TRT for symptom relief?

Answer: This is debated. Laboratory data consistently shows that clomiphene normalizes serum testosterone in most men with secondary hypogonadism. Symptom improvement (energy, libido, mood, body composition) is reported by the majority of men. However, some clinicians observe that a subset of patients report less robust symptom improvement with clomiphene compared to TRT, even when serum testosterone levels are comparable. Possible explanations include differences in intratesticular vs. peripheral testosterone distribution, estradiol modulation effects of the SERM, or individual variation. Controlled comparative data is limited.

Question: Is clomiphene safe for young men?

Answer: Clomiphene is frequently prescribed to younger men (20s–30s) with hypogonadism, particularly because it preserves fertility — a priority in this age group. It is generally considered well-tolerated in younger populations. There is no age-specific safety concern unique to younger men. The key consideration is ensuring a proper workup to identify the cause of hypogonadism (pituitary pathology, obesity, medications, etc.) before initiating any hormonal therapy.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Clomiphene citrate is a SERM that has been used off-label for male hypogonadism for decades. It blocks estrogen receptors at the hypothalamus, stimulating the body's own testosterone production through increased LH and FSH.
• Enclomiphene is the active trans-isomer of clomiphene, offering more selective estrogen receptor antagonism, a shorter half-life, and fewer estrogenic side effects from zuclomiphene accumulation. It was developed as Androxal for male hypogonadism but was not FDA-approved.
• The key advantage over TRT is fertility preservation. Both clomiphene and enclomiphene stimulate the HPG axis rather than suppressing it, maintaining or improving spermatogenesis while raising testosterone.
• Clomiphene is one of the most affordable hormone optimization options at $10–$30/month for generic tablets. Compounded enclomiphene costs $50–$150/month.
• Side effects are generally mild — visual disturbances (rare but clinically important, requiring immediate discontinuation), mood changes, headache, and GI discomfort. Enclomiphene has a more favorable side effect profile.
• Not all men respond. Clomiphene and enclomiphene are most effective for secondary hypogonadism (low T with low/normal LH). Men with primary hypogonadism (testicular failure) will not respond.
• Evidence is strong but not RCT-level for male use. Multiple retrospective studies, several controlled trials (particularly for enclomiphene), and decades of clinical experience support efficacy. However, no large Phase 3 RCT has led to FDA approval for this indication in men.

Questions to Ask a Provider

• Do my lab results suggest secondary hypogonadism (the type that responds to clomiphene)?
• Should I use clomiphene or enclomiphene based on my specific situation?
• What is the recommended starting dose and monitoring schedule?
• How will my estradiol levels be monitored and managed?
• Am I a candidate for fertility preservation with this approach?
• What are the expected timelines for lab improvement and symptom relief?
• How does this compare to TRT for my specific case?
• What visual or other side effects should I watch for?

Sources & Further Reading

Primary Clinical Evidence

• Krzastek SC, Sharma D, Engmann L (2019) — "Clomiphene citrate for the treatment of hypogonadism" — Current Urology Reports
• Kaminetsky J, Werner M, Engmann L, et al. (2013) — "A randomized controlled study of the pharmacokinetic and pharmacodynamic properties of enclomiphene citrate in secondary hypogonadism" — The Journal of Clinical Endocrinology & Metabolism
• Wiehle RD, Fontenot GK, Wike J, et al. (2014) — "Enclomiphene citrate stimulates serum testosterone in men with low testosterone while preserving sperm counts" — Fertility and Sterility
• Moskovic DJ, Katz DJ, Akhavan A, et al. (2012) — "Clomiphene citrate is safe and effective for long-term management of hypogonadism" — BJU International

Male Hypogonadism & Fertility

• Krzastek et al. (2019) — Comprehensive review: off-label clomiphene in men
• Kaminetsky et al. (2013) — Enclomiphene vs. testosterone gel: hormonal and fertility outcomes
• Wiehle et al. (2014) — Enclomiphene: testosterone normalization with preserved spermatogenesis

Long-Term Outcomes

• Moskovic et al. (2012) — Long-term safety and efficacy of clomiphene in men

Pharmacology & Isomer Profiles

• Wiehle et al. (2014) — Enclomiphene vs. zuclomiphene pharmacological differences
• Krzastek et al. (2019) — SERM pharmacology in male hypogonadism

Regulatory & Prescribing

• FDA: Clomid (clomiphene citrate) prescribing information
• WADA: Prohibited List — S4 Hormone and Metabolic Modulators

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.